Moffitt logo
    Search

    Choose a type to search within:

    All Doctors Clinical Trials Researchers
    search icon
    • Schedule
      New Patients
       
      Referring Physicians
    • Locations
      Magnolia
       
      McKinley
       
      Wesley Chapel
       
      International Plaza
       
      Moffitt at Memorial
       
      Fowler
       
      Telecomm/Intellicenter
    • Find a Doctor
    • MyMoffitt Portal
      Log In
       
      Enroll
    • Donate
    • 1-888-663-3488
    • image Search
    • Cancer Types & Treatments
        Cancers We Treat
      • Adrenal
      • Anal
      • Appendiceal (Appendix)
      • Astrocytoma
      • Basal Cell Carcinoma
      • Bladder
      • Bone Metastasis
      • Brain
      • Brain Tumor
      • Breast
      • Cervical
      • Cholangiocarcinoma (Bile Duct )
      • Colon
      • Colorectal
      • Cutaneous T-Cell Lymphoma
      • Ductal Carcinoma In Situ
      • Endometrial (Uterine)
      • Esophageal
      • Gallbladder
      • Gastrointestinal Carcinoid Tumor
      • GIST (Gastrointestinal Stromal Tumor)
      • Glioblastoma
      • Head and Neck
      • HER2 Positive Breast
      • Hodgkin Lymphoma
      • Inflammatory Breast
      • Invasive Ductal Carcinoma
      • Kidney (Renal Cell)
      • Leukemia
      • Liver (Hepatocellular)
      • Lung
      • Lymphomas (Hodgkin and Non-Hodgkin)
      • Melanoma
      • Meningioma
      • Merkel Cell Carcinoma
      • Mesothelioma
      • Metastatic Breast
      • Multiple Myeloma-Plasma Cell Tumor
      • Myelodysplastic Syndromes (MDS)
      • Neuroendocrine Tumor
      • Neurofibromatosis
      • Non-Hodgkin Lymphoma
      • Oral Cavity (Mouth)
      • Oral Cavity or Throat
      • Osteosarcoma
      • Ovarian
      • Pancoast Tumor
      • Pancreatic
      • Penile
      • Pituitary Adenoma
      • Prostate
      • Rectal
      • Sarcoma
      • Skin (Nonmelanoma)
      • Skull Base Tumors
      • Small Intestine
      • Spinal Tumor
      • Squamous Cell Carcinoma
      • Stomach (Gastric)
      • Testicular
      • Throat
      • Thymoma
      • Thyroid
      • Tongue
      • Tracheal
      • Triple Negative Breast
      • Vaginal
      • Vulvar
        Cancer Diagnostics and Treatments
      • Blood & Bone Marrow Transplant
      • Cardio-Oncology
      • Chemotherapy
      • Clinical Pathways
      • Clinical Trials
      • Endoscopic Procedures
      • Fertility Preservation
      • Gynecologic Oncology
      • Immunotherapy
      • Interventional Pain Management
      • Interventional Radiology
      • Personalized Medicine
      • Pharmacy
      • Radiation Therapy
      • Rehabilitation Services
      • Supportive Care Medicine
      • Surgical Care
      • Systemic Therapy
      • Targeted Therapy
      • Tumor Board
        Diagnostic Services
      • Radiology – Diagnostic Imaging and Interventional Radiology
      • Genetic Counseling and Genetic Testing
      • Pathology
      • Labwork and Bloodwork
      • Cancer Screenings
    • Patients & Families
        Patients and Families Resources Overview
      • International Referral Services
      • Moffitt Virtual Visits
      • Taking Care of Your Health
        Preparing For Your Appointment
      • Scheduling Your Appointment
      • MyMoffitt Patient Portal
      • Patient and Family Orientation
      • Patient Rights and Responsibilities
      • Medical Records
      • Traveling for Cancer Treatment
        Insurance & Financial Information
      • Insurance Coverage
      • Health Exchange
      • Medicare Coverage
      • Copay Assistance Program
      • Financial Assistance
      • Financial Information
      • Obtain a Cost Estimate
      • Understanding Your Bill
      • Frequently Asked Questions
        Programs & Support Services
        Patient and Family-Centered Care
        Cancer Survivorship
        Caregivers and Families
    • For Healthcare Professionals
        For Healthcare Professionals Overview
      • Clinical Perspectives
        Programs & Services
      • Adolescent & Young Adult (AYA)
      • Anesthesiology
      • BMT and Cellular Immunotherapy
      • Breast Oncology
      • Cardio-Oncology
      • Cutaneous Oncology
      • Diagnostic Imaging and Interventional Radiology
      • Endocrine Oncology
      • Gastrointestinal Oncology
      • Genetic Counseling
      • Genitourinary Oncology
      • Gynecologic Oncology
      • Head and Neck Oncology
      • Immunotherapy
      • Malignant Hematology
      • Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System
      • Neuro-Oncology
      • Pathology
      • Pharmacy
      • Radiation Oncology
      • Sarcoma
      • Screening & Prevention
      • Senior Adult Oncology
      • Supportive Care Medicine
      • Thoracic Oncology
        Physician Relations
        Continuing Education
      • Provider Conferences
      • Moffitt Grand Rounds
      • Multidisciplinary Programs
    • Research
        Research Overview
        CCSG Programs
      • Cancer Biology and Evolution
      • Cancer Epidemiology
      • Health Outcomes & Behavior
      • Immuno-Oncology
      • Molecular Medicine
        Divisions and Departments
      • Biostatistics and Bioinformatics
      • Cancer Epidemiology
      • Drug Discovery
      • Health Outcomes and Behavior
      • Immunology
      • Integrated Mathematical Oncology
      • Machine Learning
      • Metabolism and Physiology
      • Molecular Oncology
      • Tumor Biology
        Centers and Institutes
      • Institutes
      • Centers of Excellence
        Shared Resources
      • Analytic Microscopy
      • Biostatistics and Bioinformatics
      • Cancer Pharmacokinetics and Pharmacodynamics
      • Cell Therapies
      • Chemical Biology
      • Collaborative Data Services
      • Flow Cytometry
      • Gene Targeting
      • Molecular Genomics
      • Participant Research, Interventions, and Measurement Core (PRISM)
      • Proteomics and Metabolomics
      • Quantitative Imaging Core
      • Small Animal Imaging Lab
      • Tissue
        Research Education and Training
      • Office of Postdoctoral Affairs
      • Office of Graduate Affairs
      • Office of Undergraduate and Visiting Scholar Affairs
      • What We Provide
        Community Outreach, Engagement, and Equity
      • About Us
      • Catchment Area Cancer Data
      • Moffitt Outreach in the Community
      • Research in the Community
      • Education and Outreach Resources
      • Get Involved
        Innovation and Industry Alliances
      • Available Technologies
      • Business of Biotech
      • Events
      • Internship Programs
      • Technology And Innovation Fund
      • Contact Us
    • Training & Education
        Training and Education Overview
      • Moffitt Innovators of Tomorrow Symposium
        Medical Education
      • Program Staff/Contact Us
      • Our Training Programs
      • Salary and Benefits
        Research Education and Training
      • Office of Postdoctoral Affairs
      • Office of Graduate Affairs
      • Office of Undergraduate and Visiting Scholar Affairs
      • What We Provide
      • Where Are They Now
        Nursing Education
      • Oncology Nurse Residency Program
      • Ambulatory Care Oncology Nurse Residency Program
      • Registered Nurse
      • Nurse Anesthetist
      • Nurse Practitioner
        Health Professional Education
        Continuing Education
        Other Educational Programs
    • Give
        Give Overview
        Ways to Give
      • Cash, Stock or Other Assets
      • Planned Giving
      • Philanthropic Foundation Giving
      • Corporate Partnership
      • Employer Matching Gifts
      • Endowment Gifts
      • Other Ways to Donate
        Get Involved
      • Become a Member
      • Join a Community Partner Event
      • Volunteer Your Time
      • Miles for Moffitt
      • Magnolia
      • Mission Possible Sarasota Luncheon
      • Discovery Series Webinars
        Why Give?
      • About the Moffitt Foundation
      • FAQ
      • Financials and Stewardship
      • Contact the Foundation
      • You Can Make a Difference
      • 2021 Annual Foundation Impact Report
    1. Home
    2. Newsroom
    3. Press Release Archive
    4. 2016
    5. New Study Shows Nivolumab and Ipilimumab Combination Therapy is Effective for Non-Small Cell Lung Cancer Patients, Say Moffitt Researchers
    • click to share
      Facebook
      Twitter
      Linkedin
      Pinterest
      Email
    • click to print

    New Study Shows Nivolumab and Ipilimumab Combination Therapy is Effective for Non-Small Cell Lung Cancer Patients, Say Moffitt Researchers

    December 05, 2016

    TAMPA, Fla. – Lung cancer is the number one cause of cancer-related mortality in the United States, with over 158,000 deaths each year. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, affecting approximately 85 percent of lung cancer patients.  There is an urgent need to identify better initial treatment options for NSCLC to reduce the high mortality rate of this disease. Researchers from Moffitt Cancer Center and several collaborative institutions published study results today in The Lancet Oncology showing that the drug combination nivolumab and ipilimumab may be an effective initial treatment option for patients with advanced NSCLC.

    Significant strides have been made in recent years in regard to understanding the role of the immune system in tumor development. Tumors can harness the properties of the immune system to avoid detection and continue to grow and spread. Nivolumab and ipilimumab are two drugs that have been approved by the Food and Drug Administration to reactivate the immune system to recognize tumor cells and target them for destruction. 

    Nivolumab inhibits a protein called PD-1 and is approved to treat several different malignancies, including advanced NSCLC patients who were previously treated with a standard chemotherapy regimen.  Ipilimumab inhibits a protein called CTLA-4 and is approved to treat advanced metastatic melanoma. Recently, the combination of nivolumab and ipilimumab was also approved for advanced metastatic melanoma based on data showing that the combination resulted in a 60 percent reduced risk of progression or death when compared to either drug alone.

    In order to determine if the combination is also more effective in advanced NSCLC patients, the phase 1 CheckMate 012 trial was initiated.  The trial was conducted at twelve cancer centers throughout the United States and Canada, including Moffitt. The goal of the study was to determine the safety and clinical activity of nivolumab plus ipilimumab in previously untreated patients with advanced NSCLC.

    Previously published data from the CheckMate 012 study suggested that higher doses of both nivolumab and ipilimumab were intolerable to NSCLC patients.  Fifty-one percent of the patients experienced high-grade adverse events and more than 30 percent of patients had to discontinue treatment because of these toxicities. In the current publication, the researchers report additional results from the CheckMate 012 study from 77 NSCLC patients who were treated with lower drug concentrations and less frequently.

     

    The patients were treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg given either every 12 weeks (Q12W) or every 6 weeks (Q6W). The researchers report that both treatment schedules were less toxic and fewer patients discontinued treatment because of toxicities than the previously reported treatment schedules. High-grade toxicities occurred in 37 percent of the patients on the Q12W schedule and in 33 percent of patients on the Q6W schedule. The most common high-grade toxicities were altered pancreas activity, pneumonitis, altered adrenal gland activity, and colitis.

    The researchers also report that both treatment schedules were active in NSCLC patients, with 47 percent of patients in the Q12W group achieving a response and 38 percent of the patients in the Q6W group achieving a response. The majority of these responses were durable. Over 70% of patients maintained their response for an extended period of time in both treatment groups.  Importantly, the researchers determined that the nivolumab and ipilimumab combination was highly active in patients who had tumor expression of the PD-L1 protein, with 57 percent of these patients achieving a response.

    These results in NSCLC are encouraging and an ongoing phase 3 clinical trial is currently comparing the efficacy of the combination of nivolumab and ipilimumab to either nivolumab alone or standard chemotherapy in previously untreated advanced NSCLC patients.

    The study was funded by Bristol-Myers Squibb, makers of nivolumab and ipilimumab.

    About Moffitt Cancer Center
    Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 47 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, clinical trials, prevention and cancer control. Moffitt is the No. 6 cancer hospital in the nation and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer care since 1999. Moffitt devotes more than 2.5 million square feet to research and patient care. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 5,200 team members, Moffitt has an economic impact in the state of $2.1 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter and YouTube. 

     

    ###

     

     

    Twitter

    Tweets by MoffittNews
    footer logo
    • BROWSE
      • Cancer Types & Treatments
      • Careers
      • Clinical Trials
      • Diagnostic Services
      • Education & Training
      • Locations
      • Patients & Families
      • Research
    • ABOUT
      • About Moffitt
      • Available Technologies
      • Calendar of Events
      • Clinical Perspectives
      • Community Benefit
      • Diversity
      • Endeavor
      • Newsroom
      • Our Outcomes
      • Partnerships
      • Taking Care of Your Health
    • ACTION
      • Appointments
      • Find a Doctor
      • Patient Portal
      • Refer a Patient
      • Referring Provider Portal
      • Staff Login
      • Staff Access
      • Volunteer
      • Ways to Give
    Call Today 1-888-663-3488
    Link to FaceBook
    Facebook
    Link to Twitter
    Twitter
    Link to Instagram
    Instagram
    Link to YouTube
    YouTube
    nci designated comprehensive cancer center award
    nccn award
    magnet recognized award
    diversity inc award
    • Site Map
    • Privacy Policy
    • Terms & Conditions
    • Unsubscribe
    • State Nonprofit Disclosures
    • Donor Privacy
    • Notice of Privacy Practices
    • Visitor Policy
    ©Copyright 2023 Moffitt Cancer Center
    ✕

    Request an Appointment at Moffitt Cancer Center

    Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.

    NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.

    REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.

    Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.


    Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub

    ✕

    Access Your Portal

    For Patients

    A secure website for patients to access their medical care at Moffitt.

    PATIENT PORTAL LOGIN

    For Physicians

    An online resource for referring physicians and their staff.

    PROVIDER PORTAL LOGIN

    For Moffitt Staff

    For Moffitt faculty & staff members to access MoffittNet applications.

    STAFF PORTAL LOGIN

    ✕

    Call: 1-888-663-3488

    Call: 1-888-663-3488

    Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.

    Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday